Cambridge Trust Co. decreased its stake in Pfizer Inc. (NYSE:PFE) by 12.0% during the second quarter, according to its most recent filing with the SEC. The fund owned 345,200 shares of the biopharmaceutical company’s stock after selling 47,051 shares during the period. Cambridge Trust Co.’s holdings in Pfizer were worth $12,155,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in PFE. Stelac Advisory Services LLC purchased a new position in shares of Pfizer during the second quarter valued at about $110,000. Commonwealth Financial Services LLC raised its position in shares of Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 210 shares during the period. Catamount Wealth Management raised its position in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares during the period. Stuart Chaussee & Associates Inc. raised its position in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares during the period. Finally, Financial Management Professionals Inc. raised its position in shares of Pfizer by 21.9% in the second quarter. Financial Management Professionals Inc. now owns 5,517 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 993 shares during the period. Institutional investors own 69.65% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.27% on Friday, hitting $33.56. The stock had a trading volume of 14,819,706 shares. Pfizer Inc. has a 52 week low of $28.25 and a 52 week high of $37.39. The company has a 50-day moving average of $34.29 and a 200 day moving average of $34.19. The company has a market capitalization of $203.56 billion, a price-to-earnings ratio of 29.75 and a beta of 0.86.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. During the same period in the prior year, the business earned $0.56 EPS. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post $2.46 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be paid a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 3.58%. The ex-dividend date is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 95.24%.
PFE has been the topic of several research reports. Jefferies Group set a $41.50 price target on Pfizer and gave the company a “buy” rating in a research note on Thursday, July 14th. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.08 target price on the stock in a research note on Tuesday, August 2nd. JPMorgan Chase & Co. set a $40.00 target price on Pfizer and gave the company a “buy” rating in a research note on Wednesday, August 3rd. Argus reissued a “buy” rating and issued a $39.00 target price on shares of Pfizer in a research note on Tuesday, October 4th. Finally, Credit Suisse Group AG reissued an “outperform” rating and issued a $40.00 target price on shares of Pfizer in a research note on Monday, August 22nd. Ten research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.